The field of cancer immunotherapy has witnessed significant advancements in recent years, revolutionizing the landscape of cancer treatment. However, primary and secondary resistance to single-agent immunotherapy often results in treatment failure, and only a minority of patients achieve long-term benefits. One strategy to improve cancer immunotherapy is to develop new biomarkers, such as PD-L1, that can be used to select potential responders. Another strategy is to combine agents with different mechanisms of action and target multiple resistant mechanisms. Among various immunotherapeutic approaches, combinational immunotherapy has emerged as a powerful strategy harnessing the synergistic effects of multiple modalities to enhance anti-tumor immune response.
This Research Topic aims to highlight the latest research and developments in the field of novel immunotherapy targets and the development of combinational immunotherapies. By targeting these novel pathways and combining different treatment modalities, we can maximize the therapeutic potential of immunotherapy, and improve patient outcomes in various cancers. The information presented in this Research Topic will serve as a valuable resource for researchers and clinicians working towards advancing the field of immunotherapy.
We welcome Original Research articles, Reviews, and Perspectives that explore diverse aspects of new immunotherapy targets and combinational immunotherapy in breast cancers and gastrointestinal cancers. Potential subtopics include, but are not limited to:
1. Unconventional Immunotherapy Targets: explore unconventional targets for a potential role in modulating immune responses, such as novel isoforms and subcellular localization, stromal cells, tumor microenvironment components, and metabolic pathways.
2. Preclinical and clinical studies evaluating the efficacy and safety of novel combinational immunotherapies.
3. Mechanisms underlying synergistic effects of different immunotherapeutic modalities, such as immune checkpoint inhibitors, adoptive cell therapy, anti-angiogenesis, cancer vaccines, and cytokine therapies.
4. Identification and characterization of predictive biomarkers for response to immunotherapy.
5. Novel therapeutic targets and innovative approaches to design rational combinations for enhanced anti-tumor immune response.
6. Role of combinational immunotherapy in specific solid tumors, including breast and gastrointestinal cancers.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro. or in vivo.) are out of the scope for this section and will not be accepted as part of this Research Topic.
The field of cancer immunotherapy has witnessed significant advancements in recent years, revolutionizing the landscape of cancer treatment. However, primary and secondary resistance to single-agent immunotherapy often results in treatment failure, and only a minority of patients achieve long-term benefits. One strategy to improve cancer immunotherapy is to develop new biomarkers, such as PD-L1, that can be used to select potential responders. Another strategy is to combine agents with different mechanisms of action and target multiple resistant mechanisms. Among various immunotherapeutic approaches, combinational immunotherapy has emerged as a powerful strategy harnessing the synergistic effects of multiple modalities to enhance anti-tumor immune response.
This Research Topic aims to highlight the latest research and developments in the field of novel immunotherapy targets and the development of combinational immunotherapies. By targeting these novel pathways and combining different treatment modalities, we can maximize the therapeutic potential of immunotherapy, and improve patient outcomes in various cancers. The information presented in this Research Topic will serve as a valuable resource for researchers and clinicians working towards advancing the field of immunotherapy.
We welcome Original Research articles, Reviews, and Perspectives that explore diverse aspects of new immunotherapy targets and combinational immunotherapy in breast cancers and gastrointestinal cancers. Potential subtopics include, but are not limited to:
1. Unconventional Immunotherapy Targets: explore unconventional targets for a potential role in modulating immune responses, such as novel isoforms and subcellular localization, stromal cells, tumor microenvironment components, and metabolic pathways.
2. Preclinical and clinical studies evaluating the efficacy and safety of novel combinational immunotherapies.
3. Mechanisms underlying synergistic effects of different immunotherapeutic modalities, such as immune checkpoint inhibitors, adoptive cell therapy, anti-angiogenesis, cancer vaccines, and cytokine therapies.
4. Identification and characterization of predictive biomarkers for response to immunotherapy.
5. Novel therapeutic targets and innovative approaches to design rational combinations for enhanced anti-tumor immune response.
6. Role of combinational immunotherapy in specific solid tumors, including breast and gastrointestinal cancers.
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro. or in vivo.) are out of the scope for this section and will not be accepted as part of this Research Topic.